Between a medicine leaving its manufacturer and reaching a patient, it may pass through suppliers, warehouses, vehicles, hospital stores, pharmacies and health workers. At every stage, its safety can be compromised. Was it obtained from an authorised source? Was it transported and stored correctly? Has it expired? Can its movement be traced? Does the packet contain the medicine its label promises?
A failure anywhere along that chain can turn treatment into danger.
Governor Umo Eno’s proposed Akwa Ibom State Drugs and Health Supplies Management Agency Bill, 2026, seeks to establish stronger control over this process. Approved for transmission to the House of Assembly as one of the administration’s nine health reform bills, the legislation is intended to improve the procurement, storage, distribution and monitoring of medicines and other health supplies across the state.
The patient-safety implications are substantial. A doctor may diagnose an illness correctly and prescribe the appropriate treatment, yet the outcome still depends on the product eventually administered. If the medicine is counterfeit, substandard, expired, damaged by poor storage or unavailable when needed, the clinical process has already been compromised.
Treatment therefore begins long before a tablet is swallowed or an injection administered. It begins with decisions about where medicines are purchased, how suppliers are verified, where products are stored and how they are distributed to the facilities that need them.
Nigeria’s experience with substandard medicines demonstrates the importance of these controls. Counterfeit products may contain the wrong ingredients, insufficient quantities of an active ingredient or no active ingredient at all. Some imitate legitimate brands closely enough to deceive patients and health workers.
For the patient, the consequences may look like an ordinary treatment failure. A fever persists, an infection worsens or blood pressure remains uncontrolled despite medication. Additional tests may be ordered and prescriptions changed without anyone immediately recognising that the original product was ineffective or unsafe.
The danger can extend beyond the individual. Medicines containing inadequate active ingredients may contribute to antimicrobial resistance by exposing disease-causing organisms to doses too weak to eliminate them. Repeated treatment failures also weaken public confidence in healthcare.
Governor Eno’s reform is not intended to replace the national regulatory responsibilities of the National Agency for Food and Drug Administration and Control. It however, will strengthen the supply chain under state control by introducing clearer systems for procurement, storage, inventory management, distribution and the reporting of suspicious products. Such a framework will make it more difficult for medicines of uncertain origin to enter public facilities unnoticed in Akwa Ibom State.
Procurement is the first safeguard. Government health institutions purchase medicines in substantial quantities for distribution across hospitals, clinics and public health programmes. Supplier selection will be based on more than price. A product that appears inexpensive becomes extraordinarily costly if it fails to treat patients, causes harm or must later be recalled and destroyed.
The agency will establish approved procurement procedures, verify suppliers and maintain records showing the origin of each product. It will also coordinate demand across facilities so that purchases reflect actual consumption rather than fragmented requests or unreliable estimates.
Distribution creates another point of vulnerability. Medicines must travel from central stores to facilities across Akwa Ibom without being diverted, substituted, damaged or delayed. Their movement will be documented so government can determine what was dispatched, where it went, who received it and how much remained after use.
Without that visibility, shortages become difficult to explain. A facility may report that an essential medicine is unavailable even though government records show that product was purchasd. The failure lies somewhere between procurement and the patient. Effective monitoring will allow the administration to locate that point rather than treat each shortage as an unexplained event.
Modern traceability systems will strengthen this oversight through standardised barcodes, product serialisation and digital inventory records. These tools make it easier to follow medicines through the supply chain, identify affected batches during recalls and authenticate products before use.
The proposed agency will provide a clearer centre of accountability. Fragmented responsibility often allows problems to move between institutions without resolution. Procurement officials blame distributors, distributors blame facility managers and facility managers blame delayed funding or inaccurate records. The agency will coordinate these functions and make it easier to identify where failure occurred.
A prescription expresses a doctor’s clinical judgement. The supply chain determines whether the patient receives the medicine that judgement requires. By pursuing stronger control over procurement, storage, distribution and monitoring, Governor Umo Eno is seeking to ensure that what finally reaches the patient is genuine, effective and safe.
